| Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation (NCT00001561) | National Cancer Institute (NCI) | 1996-11-01 |
| Antineoplaston Therapy in Treating Patients With Multiple Myeloma (NCT00003511) | Burzynski Research Institute | 1996-04-04 |
| Autologous Transplantation for Multiple Myeloma (NCT00378222) | University of Bologna | 1996-01-01 |
| The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy (NCT00270166) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1995-02-01 |
| The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma (NCT00270101) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1995-01-01 |
| High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma (NCT00186238) | Stanford University | 1994-09-01 |
| SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma (NCT00002548) | SWOG Cancer Research Network | 1994-01-01 |
| Agriculture Health Study (NCT00352924) | National Cancer Institute (NCI) | 1993-04-30 |
| Cytogenetic Studies in Acute Leukemia and Multiple Myeloma (NCT00048958) | Alliance for Clinical Trials in Oncology | 1984-06-01 |
| Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma (NCT01632826) | Celgene | |
| Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma (NCT02666209) | Dana-Farber Cancer Institute | |
| Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma (NCT02477891) | Janssen Research & Development, LLC | |
| Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma (NCT02541643) | Sundar Jagannath | |
| Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma (NCT03850704) | Masonic Cancer Center, University of Minnesota | |
| Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma (NCT05346835) | Janssen Scientific Affairs, LLC | |
| Hematopoietic Stem Cell Transplantation in Myeloma (NCT00415987) | Azienda Ospedaliera San Giovanni Battista | |
| Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) (NCT05238311) | Pfizer | |
| Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma (NCT00036140) | Pfizer | |
| Expanded Access for CC-4047 (NCT03723096) | Celgene | |
| Expanded Access to Venetoclax (NCT03123029) | AbbVie | |
| Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release (NCT04771078) | Celgene | |
| An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma (NCT02568943) | Novartis Pharmaceuticals | |
| Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability (NCT00257114) | Millennium Pharmaceuticals, Inc. | |
| GO-203-2C + Bortezomib For Relapsed Or Refractory MM (NCT02658396) | Dana-Farber Cancer Institute | |
| A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma (NCT00096837) | Pharmacyclics LLC. | |
| Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma (NCT03126617) | Bristol-Myers Squibb | |
| Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease (NCT01410500) | Amgen | |
| Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma (NCT02204553) | Novartis Pharmaceuticals | |
| Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy (NCT01250808) | Peking University | |
| A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma (NCT01274403) | Gruppo Italiano Studio Linfomi | |
| A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients (NCT00799539) | Janssen-Ortho Inc., Canada | |
| Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma (NCT04452994) | Janssen Research & Development, LLC | |
| Serum Free Light Change in Multiple Myeloma (NCT00910078) | Azienda Ospedaliera San Giovanni Battista | |
| Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131 (NCT01296204) | Centre René Gauducheau | |
| Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) (NCT05164250) | Regeneron Pharmaceuticals | |
| Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies (NCT00036023) | Amgen | |
| This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. (NCT00720603) | Genzyme, a Sanofi Company | |
| A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies (NCT00162500) | Hadassah Medical Organization | |
| Karyopharm Expanded Access Program for Selinexor (NCT07215832) | Karyopharm Therapeutics Inc | |
| Expanded Access Treatment Protocol CA204-143 (NCT02368301) | Bristol-Myers Squibb | |
| Early Patient Access Treatment Use Protocol CA204-220 (NCT02856438) | Bristol-Myers Squibb | |
| A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE (NCT00063791) | Millennium Pharmaceuticals, Inc. | |
| Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT00995059) | Mayo Clinic | |
| Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) (NCT05161598) | Janssen Research & Development, LLC | |
| Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma (NCT03763370) | GlaxoSmithKline | |
| TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma (NCT00243763) | Novartis | |
| Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (NCT05462639) | Pfizer | |
| Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma (NCT04453397) | TeneoOne Inc. | |